Case Report - Interventional Cardiology (2018) Volume 10, Issue 2

PCSK9 Inhibitors-angiographically Proved Efficacy To Stop Aggressive Ischaemic Heart Disease Progression

Corresponding Author:
Zebrauskaite A
Department of Cardiology
University Hospital Limerick, Ireland
Tel: 91-9323361116
E-mail: Zebrauskaite.aiste@gmail.com

Submitted: March 21, 2018 Accepted: April 23, 2018 Published online: April 30, 2018

Abstract

It is well established that elevated level of cholesterol is the main factor for development and progression of cardiovascular disease (CVD). Low-density lipoprotein cholesterol (LDL-C) has been strongly associated with CVD. Lowering LDL-C reduces atherosclerotic disease risk and progression, irrespectively of how the reductions are achieved. The efficacy of statins is well known and proved by multiple trials. But the target LDL-C level cannot always be achieved by using maximally tolerated statin dose, overwise there are part of patients who have an intolerance for the statin. The new group of lipid-lowering drugs - PCSK9 inhibitors (PCSK9I) is monoclonal antibodies that bind to serum PCSK9 and delay LDL receptor degradation. Two PCSK9I are commercially available: evolocumab and alirocumab. Indications to use PCSK9I include LDL-C lowering on maximally tolerated statin therapy in patients with CAD or Familial Hypercholesterolemia. We present a case report of a 70-year-old lady with aggressively progressive ischaemic heart disease (IHD) and intolerance to the statin. Great clinical and angiographical improvement was achieved by prescribing PCSK9I.

Introduction

It is well established that elevated level of cholesterol is the main factor for development and progression of cardiovascular disease (CVD). Low density lipoprotein cholesterol (LDL-C) has been strongly associated with CVD [1-5]. Lowering LDL-C reduces atherosclerotic disease risk and progression, irrespectively of how the reduction is achieved [1-2,6]. The efficacy of statins is well known and proved by multiple trials [7]. But the target LDL-C level cannot always be achieved by using maximal tolerated statin dose, overvise there are part of patients who have intolerance for statin. The new group of lipid lowering drugs – PCSK9 inhibitors (PCSK9I) are monoclonal antibodies that bind to serum PCSK9 and delay LDL receptor degradation [8]. Two PCSK9I are commercially available: evelocumab and alirocumab. Indications to use PCSK9I include LDL-C lowering on maximally tolerated statin therapy in patients with CAD or Familial Hypercholesterolemia [1-2,6].

Case Report

We present a case report of 70 year old lady with aggressively progressive ischaemic heart disease (IHD) and intolerance to statin. Great improvement was achieved by prescribing PCSK9I. Patient has a background history of high blood pressure, dyslipidaemia, intolerance to statin, positive IHD family history.

For this lady IHD presented as inferior ST elevation myocardial infarction at age 64. Angiogram revealed sub-occlusion of right coronary artery (RCA) and mild to moderate changes in left anterior descending (LAD) and left circumflex (LCx) arteries. RCA was stented with drug eluting stent (DES) dual antiplatelet therapy (DAPT) and statin was prescribed. Initial LDL-C was 6.0 mmol/l. After 3 months statin was stopped due to elevated liver enzymes. We started Ezetimib which was stopped in two-week time because of gastrointestinal tract irritation.

Patient had progression of angina symptoms; she got repeated angiograms and treatment with DES every year: LCx stenting in 2012, LAD stenting in 2013-2014, and posterior left ventricular (PLV) artery of RCA stenting in 2015. LDL-C was 6.0 mmol/l. PCSK9I Alirocumab injections every two weeks were prescribed. We got good response to PCSK9I. LDL-C decreased up to 3.0 mmol/l. Lowering LDL-C levels stopped IHD progression. We performed repeated angiograms in 2016 and 2017, there were no significant IHD progression seen. All examples of performed angiograms and stentings are shown in Figures 1-6. Angina symptoms stay stable. Patient has a great improvement in exercising capacity and in quality of life.

interventional-cardiology-Angiogram-RCA

Figure 1: Angiogram and RCA stenting in 2011.

interventional-cardiology-LCx-stenting

Figure 2: Angiogram and LCx stenting in 2013.

interventional-cardiology-LAD-stenting

Figure 3: Angiogram and LAD stenting in 2014.

interventional-cardiology-PLV-stenting

Figure 4: Angiogram and PLV stenting in 2015.

interventional-cardiology-right-coronary

Figure 5: Angiogram in 2016.

interventional-cardiology-coronary-artery

Figure 6: Angiogram in 2017.

Discussion

Efficacy and safety of two PCSK9I agents’ evelocumab and alirocumab when prescribed on the top of statin was proved by two large randomized trials. They were shown to reduce LDL-C levels by approximately 60% that results in decreasing rates of coronary events and stabilisation of IHD [9-10]. Coronary events reduction was related to decrease LDL-C levels. It is proved that statins have not only LDL-C lowering but also a cardiovascular pleiotropic effect [11-12]. There are no evidences that PCSK9I alone can have the similar effect.

Guidelines recommend to prescribe PCSK9I for patients who has insufficient control of LDL-C levels with maximal tolerated statin dose, for patients who have statin intolerance and for patients with familial hypercholesterolemia combined with statin [1-2,6]. However, there are no data about PCSK9 efficacy in reducing cardiovascular events rate if prescribed alone even for patient with intolerance to statin.

Our patient was treated with PCSK9I alone, and we observed good clinical and angiographic effect. We did not reach the target recommended LDL-C level<1.8mmol/l, but recommended LDL-C reduction up to 50% was achieved [1-2,6]. LDL-C reduction by 50% was enough to stop IHD progression, keep angina symptoms stabile and improve patient’s exercise capacity.

References

Awards Nomination 20+ Million Readerbase

Select your language of interest to view the total content in your interested language

Journal Metrics:

Impact Factor 1.34
Scimago Journal Rank (SJR) 123
SJR Total Cites 15
Source Normalized Impact per Paper (SNIP) 0.144
h-index (2023) 12
PubMed NLM ID:  10148499
Google Scholar h5 index: 6
Iindex Copernicus Value: 105.52


Google Scholar citation report
Citations : 1297

Interventional Cardiology received 1297 citations as per Google Scholar report


Interventional Cardiology peer review process verified at publons

Indexed In

flyer